Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

ATOMIC Trial

Full trial name: A multi-centre open-label two-arm randomised superiority clinical trial of Azithromycin versus usual care In Ambulatory COVID-19

Principal Investigator: Dr Timothy SC Hinks (Nuffield Department of Medicine)

Summary: The ATOMIC study is investigating if a common antibiotic called Azithromycin (AZM) may prevent the patients from getting worse. Azithromycin is a safe, inexpensive, antibiotic that is available worldwide and is often prescribed by doctors across the world and it has been proved to have a wide range of antibacterial, anti-inflammatory and antiviral properties. Doctors think that Azithromycin, due to how it works, may be able to control excessive inflammation in the lung alongside its anti-viral and antibacterial effects which could help prevent progression to the severe form of the COVID-19 disease where people end up needing hospital care.

Read more about the trial

CATALYST Trial

Principal Investigators: Professor Duncan Richards (Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences) and Dr Matt Rowland (Nuffield Department of Clinical Neurosciences)

Summary: The overall aim of the CATALYST Trial is to guide the selection of new drug interventions for large phase III trials in hospitalised patients with COVID-19 infection. It is hoped that by using drugs that target the most serious symptoms of the virus, the severity of the disease could be mitigated, leading to a reduction in the number of patients needing to be admitted to intensive care and ultimately, a reduction in virus-related deaths.

Read more about the trial

COPCOV Trial

Principal Investigators: Professor Nicholas White and Dr William Schilling (MORU Tropical Health Network)

Summary: The COPCOV trial is a randomized clinical trial comparing chloroquine or hydroxychloroquine vs. placebo as prophylaxis against COVID-19 in healthcare settings. The study, run in over a dozen countries in Europe, Africa and Asia, will enroll 40,000+ vital frontline health care workers and staff who have close contact with COVID-19 patients to determine whether chloroquine or hydroxychloroquine are effective in preventing COVID-19.

Read more about the trial

Co-SPACE Study

Full study name: COVID-19 Supporting Parents, Adolescents and Children in Epidemics

Principal Investigator: Professor Cathy Cresswell (Department of Experimental Psychology / Department of Psychiatry)

Summary: The Co-SPACE study aims to track children and young people’s mental health throughout the COVID-19 crisis. Survey results will help researchers identify what protects children and young people from deteriorating mental health, over time, and at particular stress points, and how this may vary according to child and family characteristics. It also aims to identify what advice, support and help parents would find most useful.

Read more about the study

COVID-19 Convalescent Plasma Programme

This programme is being led by NHS Blood and Transplant

Oxford Lead: Professor David Roberts (Radcliffe Department of Medicine)

Summary: The Convalescent Plasma Programme collects convalescent plasma from people who have recovered from COVID-19 to support a national clinical trial. The trial will investigate whether plasma transfusions could improve a COVID-19 patient’s speed of recovery and chances of survival. The first donations have now been collected and the first transfusions will follow later this month. The transfusions will be done through the existing REMAP-CAP trial and further trial options are being explored.

Read more about the trial (NHS Blood & Transplant website)

COVID-19 Infection Study

This trial is being led by Department of Health & Social Care and the Office for National Statistics

Oxford Lead: Professor Sarah Walker (Nuffield Department of Medicine)

Summary: The COVID-19 Infection Study will contact 20,000 households across England help to understand levels of immunity and hopes to reach up to 300,000 people in the next 12 months. Participants in the study will form a representative sample of the entire UK population by age and geography. The results will help scientists and the government in the ongoing response to the coronavirus outbreak, with initial findings expected to be available in early May.

Read more about the trial

COVID-19 Oxford Vaccine Trial

Principal Investigators: Professor Sarah Gilbert, Professor Teresa Lambe, Dr Sandy Douglas, Professor Catherine Green and Professor Adrian Hill (Jenner Institute, Nuffield Department of Medicine) and Professor Andrew Pollard (Oxford Vaccine Group, Department of Paediatrics)

Summary: A team of Oxford researchers started work designing a vaccine on Saturday 10 January 2020. The current status is that they have identified a vaccine candidate and are working towards the first clinical testing phase.

Read more about the trial

ICENI Trial

Principal Investigators: Professor Duncan Richards (Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences)

Summary: The ICENI Trial will investigate whether administering the anti-inflammatory drug infliximab (which blocks TNFa) to hospital patients with COVID-19 at risk of deterioration can prevent progression to intensive care. They will also explore exactly how the drug works to reduce inflammation caused by COVID-19 by taking blood and other samples.

Read more about the trial

INTERCOVID Study

Full Study Name: A prospective cohort study of the effects of COVID-19 in pregnancy and the neonatal period

Principal Investigators: Professor José Villar, Professor Aris Papageorghiou and Professor Stephen Kennedy (Nuffield Department of Women’s & Reproductive Health)

Summary: The INTERCOVID study will provide women, families, health care providers and policy makers with high-quality evidence regarding the effects of Covid-19 in pregnancy on the health of the mother, fetus and newborn.

Read more about the study

ORCHID National Primary Care Digital Trial and Surveillance Platform

Full Study Name: Oxford Royal College of General Practitioners Clinical Informatics Digital Hub

Principal Investigators: Professor Richard Hobbs and Professor Simon de Lusignan (Nuffield Department of Primary Care Health Sciences)

Summary: This study brings together data from these GP practices to create the Oxford Royal College of General Practitioners Clinical Informatics Digital Hub (ORCHID). ORCHID will support four major research projects related to COVID-19. These are called the COVID-19 Observatory that tracks cases of coronavirus in England, the PRINCIPLE Trial that investigates which treatments are effective for coronavirus, RAPTOR-C19 which will assess which tests are accurate to diagnose coronavirus in the community, and DECISION-COVID that uses data from GP health records to find out which patients are most at risk of developing severe coronavirus needing hospital treatment.

Oxford ARC Study

Full study name: Oxford Achieving Resilience during COVID-19

Principal Investigator: Professor Elaine Fox (Department of Experimental Psychology)

Summary: The Oxford ARC study investigates resilience and how adolescents and their parents/carers are coping with social isolation during the COVID-19 (coronavirus) pandemic. They want to find out why some young people cope extremely well with stressful situations, while others find it more difficult. They also hope to better understand how psychological factors relating to worry, resilience, and social isolation affects the mental health of adolescents and their parents/carers during the challenges and uncertainties of this pandemic.   

Read more about the study

PRINCIPLE Trial

Full trial name: Platform Randomised trial of INterventions against COVID-19 In older peopLE (PRINCIPLE)

Principal Investigator: Professor Christopher Butler (Nuffield Department of Primary Care Health Sciences)

Summary: The PRINCIPLE trial aims to find out whether selected treatments given to people at higher risk of becoming more ill when they are infected with COVID-19 can help reduce the need for hospitalisation and the length of stay required, helping people recover quicker and with fewer complications. The trial is recruiting participants through GP practices across the UK.At present, we are only recruiting people through GP practices that have agreed to participate in the trial.

Read more about the study

RECOVERY Trial

Full trial name: Randomised Evaluation of COV-id19 thERapY (RECOVERY)

Principal Investigators: Professor Peter Horby (Nuffield Department of Medicine) and Professor Martin Landray (Nuffield Department of Population Health)

Summary: The RECOVERY trial is testing a number of medicines recommended by an expert panel advising the Chief Medical Officer for England. The trial is being conducted in over 130 NHS hospitals across the UK. Adult patients who have been admitted to hospital with COVID-19 are being invited to take part. The trial is specially designed so that as further medicines are identified, these can be added to the study within days.

Read more about the trial

SEBCOV Study

Principal Investigator: Professor Phaik Yeong Cheah (MORU Tropical Health Network)

Summary: The SEBCOV study aims to produce evidence to inform non-pharmaceutical interventions such as communications, quarantine, self-isolation, social distancing, travel restrictions and other public health measures for the COVID-19 pandemic. The study will run in four countries: UK, Thailand, Italy and Malaysia’

Read more about the study

On this page